Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open ‐label, single‐arm, noncomparative trial

ConclusionNeoadjuvant therapy with bevacizumab plus XELOX was well tolerated and effective in previously untreated metastatic colorectal cancer patients with initially unresectable liver metastases.

Source: Asia-Pacific Journal of Clinical Oncology - August 1, 2017 Category: Cancer & Oncology Authors: Hong ‐Hwa Chen, Jen‐Kou Lin, Joe‐Bin Chen, Chieh‐Han Chuang, Mei‐Ching Liu, Jen‐Yi Wang, Chung‐Rong Changchien Tags: ORIGINAL ARTICLE Source Type: research